Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
- MHLW Pharma Bureau Chief Tarumi Tapped to Lead Coronavirus Reponses, Mitsuaki Kamata to Take Over
March 25, 2020
- Drug Pricing Rules to Be Applied to Zolgensma: Chuikyo
March 25, 2020
- Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
- Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
- Japan’s First Ophthalmology Regenerative Medicine Product Approved: J-TEC
March 23, 2020
- Japan Eases 30-Day Inspection Rules to Expedite Coronavirus Trials
March 23, 2020
- MHLW Issues COVID-19 Treatment Guide
March 19, 2020
- Increase Copay for OTC-Like Drugs under New Mixed-Care Scheme: Professor
March 19, 2020
- 3 Key Antibiotics to Receive Price Raises through Unprofitability Re-Pricing
March 18, 2020
- Japan Grants Orphan Status to 7 Drugs
March 18, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Health Minister Reiterates Support for COVID-19 Drug Development; MHLW Accelerating Rollout of Quick Testing
March 18, 2020
- Japan to Launch Panel on Stable Drug Supplies after Cefazolin Woes; Coronavirus Outbreak Possibly Up for Discussion
March 17, 2020
- Revised Special Flu Law Enforced; Japan Can Now Declare Emergency over COVID-19
March 16, 2020
- Japan, US Agree to Work Together to Develop COVID-19 Treatments: Abe
March 16, 2020
- Japan Enacts State of Emergency Bill over Coronavirus
March 13, 2020
- Japan’s Stance to Look at Overseas Examples for Copay Raises Called into Question
March 13, 2020
- PMDA Prepares “Special Leave” System for Coronavirus Infected Staffers
March 13, 2020
- Annual Drug Price Revisions “Practically Feasible”: Health Policy Advisor
March 12, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…